MegatrendsMegatrends: not the usual suspects, but who actually profits.View megatrends →

Metrics as of 10/17/2026, 10:15 AM (Berlin time), refresh in progress.

Sanofi Stock

Sanofi

SNY.TOTSXMarkt
CA$18.60
-0.3% today

Company data

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
France
CEO
Belén Garijo López
Employees
76,493
Market cap
$22.2 B
IPO
02/12/2025

Sanofi is a healthcare company operating within the drug manufacturers, general industry, headquartered in Paris, France. Founded in 1973, the company employs 76,493 employees and is listed on the TSX. Sanofi engages in the research, production, and distribution of pharmaceutical products across all geographical…

Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.

Sanofi stock: price history

02/12/25-17.6 %16/10/26

1D

-0.1%

1W

-0.1%

1M

-3.3%

6M

-12.6%

YTD

-12.7%

1Y

–

2Y

–

5Y

–

10Y

–

Ask the agents about Sanofi

Free float & liquidity

FREE FLOAT

–

FLOAT SHARES

1,092,443,031

AVG. DAILY VOLUME (30D)

829

Dividends

EX-DATEPAY DATEAMOUNTYIELD
06/05/202614/05/2026CA$0.804.2 %

Comparable stocks

Frequently asked questions about Sanofi stock

What does Sanofi do?

Sanofi is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in France.

The CEO is Belén Garijo López, the company employs around 76,493 people.

The IPO was on 02/12/2025; the stock trades on TSX under the ticker SNY.TO.

Does Sanofi pay a dividend?

Yes. The last dividend was CA$0.80 per share, ex-date 06/05/2026, paid on 14/05/2026.

Which stocks are comparable to Sanofi?

Comparable stocks include Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Roche Holding, Amgen, Gilead Sciences and Pfizer.

How can I get Sanofi stock analyzed?

Clicking "Analyze stock" lets five strategies assess Sanofi against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.

Not investment advice. Past performance is not an indicator of future results.